Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SUPNVery BearishResearch Analysisnews

High materiality9/10

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

Feb 19, 2025, 10:49 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Failed trial data typically leads to a sharp decline in stock value. Recent similar cases show significant drops following poor clinical results.

AI summary

What happened, with direct paths to the underlying reporting

Phase 2b study of SPN-820 failed to meet primary endpoint for depression. No significant difference between SPN-820 and placebo was found. Safety profile for SPN-820 remains consistent with past trials. Onapgo injection approved, set for market in Q2 2025. SUPN stock down 14.10% following trial results.

Phase 2b study of SPN-820 failed to meet primary endpoint for depression.
No significant difference between SPN-820 and placebo was found.
Safety profile for SPN-820 remains consistent with past trials.
Onapgo injection approved, set for market in Q2 2025.
SUPN stock down 14.10% following trial results.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug